Kanat, MustafaYildiz, OzcanTunckale, Ayd N.Ceyhan, Banu OzturkKaragoz, YalcinAltuntas, YukselOguz, Aytekin2024-09-252024-09-2520101301-2193https://hdl.handle.net/20.500.12491/13277Objective: Statin therapy is well known to reduce inflammatory markers such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP). However, whether this relationship is maintained in the setting of targeting very low levels of LDL (<70 mg dl) in patients with type 2 diabetes has not been clearly established. Materials and Methods: We measured hsCRP, IL-6, and TNF-alpha in 43 subject enrolled into the multicenter, open-label, crossover prospective study evaluating the effects of lipid-lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST study). Subjects with diabetes and coronary artery disease were treated with 80 mg of atorvastatin for 12 weeks. The effect of treatment on pro-inflammatory markers was assessed after 12 weeks. Results: High-dose atorvastatin treatment significantly reduced the plasma levels of IL-6 and hsCRP (p<0.05, p<0.001, respectively), but not of TNF-alpha (p=0.051). Conclusion: Atorvastatin treatment targeting very low LDL-cholesterol level reduced the levels of several important inflammatory markers in patients with type 2 diabetes and coronary heart disease.eninfo:eu-repo/semantics/closedAccessAtorvastatinhsCRPinterleukin-6TNF-alphatype 2 diabetesArticle1423134WOS:000217309300003N/A